Evidence map›Paper›PMID 41632088›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

CD3ɛ Nanobody-Engineered Extracellular Vesicles Driving In Vivo Generation of TCE-secreting CAR-Ts for Solid Tumor Therapy With Memory Response and Minimal Immunogenicity.

Shi-Wei Huang, Yu-Chuan Lin, Chih-Ming Pan, Yeh Chen, Ming-You Shie, Cheng-Yu Chen, Kai-Wen Kan, Yi-Wen Chen, Ming-Chao Liu, Chung-Chun Wu and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Nanomaterials Drive In Vivo CAR Immune Cells Engineering.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Shi-Wei HuangTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.ORCID https://orcid.org/0000-0002-0050-0959
Yu-Chuan LinDepartment of Research and Development, Shine-On BioMedical Co. Ltd., Taichung, Taiwan.
Chih-Ming PanTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Yeh ChenDepartment of Food Science and Biotechnology, National Chung-Hsing University, Taichung, Taiwan.
Ming-You ShieResearch & Development Center for x-Dimensional Extracellular Vesicles, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Cheng-Yu ChenResearch & Development Center for x-Dimensional Extracellular Vesicles, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Kai-Wen KanResearch & Development Center for x-Dimensional Extracellular Vesicles, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Yi-Wen ChenResearch & Development Center for x-Dimensional Extracellular Vesicles, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Ming-Chao LiuDepartment of Manufacturing, Production & Manufacturing Division, Ever Supreme Bio Technology, Taichung, Taiwan.
Chung-Chun WuTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Yu-Ting ChiangTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Huai-Ping HoTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Chen-Yu LinTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Pei-Ying LinTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Yu-Han HuangTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Steffany RusliTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Wan-Yu MaoTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Pei-Wen HuangTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Sin-Ting WangShine Out Bio Medical International Co. Ltd., Taichung, Taiwan.
Wan-Chen TsaiTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Ya-Hsu ChiuTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Ting-Hsun LinTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Wan-Ling ChiangTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Che-Kai ChangTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Zi-Lun LaiDepartment of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan.
Mei-Chih ChenTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Shao-Chih ChiuTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Der-Yang ChoTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.ORCID https://orcid.org/0000-0002-6429-3565

Funding

China Medical University Hospital DMR-CARGDT-01China Medical University Hospital EXO-112-011China Medical University Hospital EXO-113-013China Medical University Hospital EXO-113-014Ministry of Education MOHW108-TDU-B-212-124024Ministry of Science and Technology CMP: NSTC 112-2320-B-039-013-Ministry of Science and Technology DYC: MOST 112-2321-B-039 -008Ministry of Science and Technology SCC: MOST 112-2314-B-039 -053Ministry of Science and Technology SWH: MOST 112-2314-B-039 -052
6 · The paper itself

Abstract

In vivo generation of chimeric antigen receptor-T (CAR-T) cells offers an innovative approach to CAR-T therapy; however, current in vivo CAR-T technologies rely on synthetic carriers or viral particles, which raise immunogenicity and safety concerns in clinical applications. Extracellular vesicles (EVs) are cell-derived natural nano-platforms with improved biocompatibility and the potential to deliver the transgene for in vivo CAR-T generation. In this study, we pioneered a CD3ε nanobody (Nb)-CD63 chimeric construct and stably expressed it on HEK-293T cell-derived EVs to produce CD3ε-targeting EVs, which were further loaded with Nb-CAR.TCE (Nb-CAR with secretable bispecific T-cell engager) transgene through electroporation. The CD3ε-Nb EVs selectively delivered Nb-CAR.TCE transgene into CD3

Indexed as

CD3 ComplexExtracellular VesiclesImmunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenSingle-Domain AntibodiesT-LymphocytesAnimalsFemaleHEK293 CellsHumansMiceCD3 ComplexCD3E protein, humanReceptors, Chimeric AntigenSingle-Domain AntibodiesCD3chimeric antigen receptorextracellular vesiclesin vivoT cell memory

Identifiers

PMID41632088
PMCPMC13045241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.